Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery

被引:0
|
作者
Miller, Heather [1 ]
Matsuo, Koji M. [1 ]
Roman, Lynda D. [1 ]
Yessaian, Annie A. [1 ]
Pham, Huyen Q. [1 ]
Hom, Marianne [1 ]
Castaneda, Antonio [1 ]
Pham, Anthony [2 ]
Ragab, Omar [2 ]
Muderspach, Laila [1 ]
Ciccone, Marcia [1 ]
Brunette, Laurie L. [1 ]
机构
[1] Univ Southern Calif, Div Gynecol Oncol, 2020 Zonal Ave,IRD 526, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Dept Radiat Oncol, Los Angeles, CA 90033 USA
关键词
Adjuvant hysterectomy; Cervical cancer; Chemoradiation; Complication; Fistula; Hysterectomy; Vaginal cuff; VAGINAL CUFF DEHISCENCE; EXTRAFASCIAL HYSTERECTOMY; RADIATION-THERAPY; CARCINOMA; BRACHYTHERAPY; SURVIVAL;
D O I
10.1186/s13014-021-01843-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Adjuvant hysterectomy following chemoradiation for bulky, early stage cervical cancer has been shown to decrease local relapse rate. The objective of this study is to compare complications and recurrences between minimally invasive and open adjuvant hysterectomy for early stage cervical cancer. Methods Patients were identified who had undergone adjuvant hysterectomy following chemoradiation for 2009 FIGO stage IB2 and IIA2 cervical cancer from August 2006 to June 2018. Demographic information, treatment course, complications, recurrence data were retrospectively extracted from the medical record. Frequency of complications was compared with Fisher exact test or chi-square test as appropriate and inverse probability of treatment propensity score weighting was used to calculate the disease-free survival. Results Fifty-four patients met inclusion criteria with a median follow up time of 60.4 months (interquartile range 28.0-98.1 months). There were 24 (44%) open versus 30 (56%) minimally invasive hysterectomies performed. The overall grade 2 or worse complication rate was 43%. There were 8 (27%) patients with complications in the minimally invasive group compared to 4 (17%) in the open group (OR 1.82 (95% CI 0.5-7.0)). There were 9 vaginal cuff defects, dehiscences and/or fistulas in the minimally invasive group compared to 3 in the open group (OR 3.0 (95% CI 0.8-11.2)). There was no statistically significant difference between disease free survival and overall survival among the two groups, however there was a trend towards decreased disease-free survival in the minimally invasive group. Conclusions Among women undergoing adjuvant hysterectomy following chemoradiation for bulky, early stage cervical cancer, there was no difference in complication rates between an open or minimally invasive surgical approach. However, the overall complication rate was high, including a high rate of vaginal cuff defect, dehiscence and/or fistulas. Our findings suggest that an adjuvant hysterectomy should be reserved for patients in which chemoradiation is not anticipated to successfully treat the primary tumor and, if performed, an open approach should be considered.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer
    Zhang, Yong
    Tang, Xiaobi
    Ma, Shanshan
    Shen, Meizhu
    Jiang, Li
    Yuan, Wenchao
    Wang, Rensheng
    Wu, Fang
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [42] A Retrospective study of early stage (IB1-IIA2) cervical cancer patients with lymphatic metastasis treated with primary chemoradiation versus radical hysterectomy followed by ajuvant chemoradiation
    Zhang, N.
    Zheng, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 501 - 501
  • [43] Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: A cost effectiveness analysis
    Jewell, Elizabeth L.
    Kulasingam, Shalini
    Myers, Evan R.
    Secord, Angeles Alvarez
    Havrilesky, Laura J.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (03) : 532 - 540
  • [44] Stage IB2 cervical cancer: A decision analysis comparing quality-adjusted survival associated with chemoradiation versus radical surgery with tailored adjuvant chemoradiation
    Einstein, M.
    Hollenberg, J.
    Hartenbach, E.
    Chappell, R.
    Kushner, D.
    Evans, A.
    Connor, J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S28 - S29
  • [45] Primary radical hysterectomy in early stage locally advanced (IB2, IIA > 4cm) cervical cancer
    Sartori, E
    Zanagnolo, V
    Tisi, G
    Pasinetti, B
    La Face, B
    Pecorelli, S
    Bianchi, UA
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 455 - 459
  • [46] Primary Surgical Management With Tailored Adjuvant Radiation for Stage IB2 Cervical Cancer
    Hacker, Neville F.
    Barlow, Ellen L.
    Scurry, James
    Gebski, Val
    Farrell, Rhonda
    Robertson, Greg
    Friedlander, Michael L.
    Jackson, Michael
    OBSTETRICS AND GYNECOLOGY, 2013, 121 (04): : 765 - 772
  • [47] Phase II study of gemcitabine and concurrent radiation followed by adjuvant hysterectomy in stage IB2 and IIA cervical carcinoma
    Yessaian, A. A.
    Roman, L. D.
    Tsao-Weil, D. D.
    Bahador, A.
    Pham, H. P.
    Muderspach, L. I.
    Groshen, S.
    Bumett, A.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S100 - S100
  • [48] Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer
    Havrilesky, LJ
    Leath, CA
    Huh, W
    Calingaert, B
    Bentley, RC
    Soper, JT
    Secord, AA
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 429 - 434
  • [49] The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancer
    Morice, P.
    Uzan, C.
    Zafrani, Y.
    Delpech, Y.
    Gouy, S.
    Haie-Meder, C.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (01) : S122 - S124
  • [50] PHASE I DOSE ESCALATION STUDY OF WEEKLY PACLITAXEL AND CISPLATIN FOLLOWED BY RADICAL HYSTERECTOMY IN STAGES IB2 AND IIA2 CERVICAL CANCER
    Huang, H. J.
    Chou, H. H.
    Lin, H.
    Yang, L. Y.
    Hsueh, S.
    Liu, F. Y.
    Liou, Y. L.
    Liou, J. D.
    Chen, M. Y.
    Chao, A.
    Chang, T. C.
    Lai, C. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1173 - 1173